Lumida
/RVMD
⌘K
Revolution Medicines Inc

Revolution Medicines Inc

RVMD
$203.77USD+0.21%+0.42 today

MARKET CAP

43.7B

P/E (TTM)

FWD P/E

DAY RANGE

$198 – $206

52W RANGE

$42
$224

AI Summary

Stalk
StalkMedium

RVMD remains in a Stage 2 uptrend with no active structural patterns, but price is currently rejecting at the 9- and 20-day EMAs and pulling back into the rising 50-day SMA. We maintain a medium-term bullish bias and will stalk for a firm hold and eventual reclamation of the faster EMAs around the 50-day SMA. A decisive break and close below the 50-day SMA with follow-through selling would invalidate the medium-term bullish bias.

  • FDA approved RASONQUE for metastatic pancreatic cancer with analysts forecasting $11.5B peak sales.
  • Phase 1/2 trials showed 42% confirmed response rate and 16-month median overall survival.
  • Q2 2026 net loss of $644M vs $248M prior year highlights profitability risk.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2021FY 2022FY 2023TREND
Sales, Adj.$43.0M$29.4M$35.4M$11.6M
YoY %-31.6%+20.4%-67.3%
P / Sales50.5x62.4x52.3x275.8x
EV / Sales50.3x63.3x51.3x236.1x
Gross Profit, Adj.$43.0M$29.4M$35.4M$11.6M
YoY %-31.6%+20.4%-67.3%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit50.3x63.3x51.3x236.1x
EBITDA, Adj.$-104.2M$-180.7M$-253.2M$-481.1M
YoY %-73.5%-40.2%-90.0%
Margin %-242.3%-614.8%-715.8%-4154.4%
EV / EBITDA-20.7x-10.3x-7.2x-5.7x
EBIT$-110.7M$-188.0M$-258.3M$-487.2M
YoY %-69.8%-37.4%-88.6%
Margin %-257.5%-639.7%-730.0%-4207.1%
EV / EBIT-19.5x-9.9x-7.0x-5.6x
Net Income$-110.4M$-187.1M$-248.7M$-436.4M
YoY %-69.5%-32.9%-75.5%
Net Margin-256.8%-636.6%-703.0%-3768.3%
EPS (GAAP)-$2.01-$2.57-$3.08-$3.86
YoY %-27.9%-19.8%-25.3%